Li Jonathan
Brigham and Women's Hospital at Harvard Medical School in Boston, MA, USA.
Top Antivir Med. 2020 Jan;27(4):91-95.
Achieving a cure for HIV remains a priority in HIV research. Two cases of 'sterilizing cure' have been observed-in Timothy Ray Brown and the "London" patient; both patients received allogeneic hematopoietic stem cell transplantation (HSCT) from donors homozygous for the CCR5-delta 32 deletion, which impairs function of an HIV coreceptor on host cells. Other strategies that have been evaluated for achieving sterilizing cure or functional cure--ie, sustained virologic remission in the absence of antiretroviral therapy (ART)-include: HSCT with wild-type CC chemokine receptor (CCR5); early ART to limit size of the HIV latent reservoir; shock and kill strategies using latency reversing agents and/or anti-HIV broadly neutralizing antibodies; and gene therapy, including attempts to modify CCR5 genes, HIV proviruses in autologous host cells, or enhanced T cells. This article summarizes a presentation by Jonathan Li, MD, MMSc, at the International Antiviral Society-USA (IAS-USA) continuing education program held in Atlanta, Georgia, in March 2019.
实现治愈艾滋病病毒仍是艾滋病研究的首要任务。已观察到两例“绝育治愈”病例——蒂莫西·雷·布朗和“伦敦”患者;两名患者均接受了来自CCR5-Δ32缺失纯合子供体的异基因造血干细胞移植(HSCT),该缺失会损害宿主细胞上艾滋病病毒共受体的功能。为实现绝育治愈或功能性治愈(即在无抗逆转录病毒疗法(ART)的情况下实现持续病毒学缓解)而评估的其他策略包括:使用野生型CC趋化因子受体(CCR5)进行HSCT;早期ART以限制艾滋病病毒潜伏库的规模;使用潜伏逆转剂和/或抗艾滋病病毒广泛中和抗体的“激活并杀死”策略;以及基因治疗,包括尝试修饰CCR5基因、自体宿主细胞中的艾滋病病毒前病毒或增强T细胞。本文总结了医学博士、医学硕士乔纳森·李于2019年3月在佐治亚州亚特兰大举行的美国国际抗病毒协会(IAS-USA)继续教育项目上的一次演讲。